Neuroinflammation and Complexes of 17 beta-Hydroxysteroid Dehydrogenase type 10-Amyloid beta in Alzheimer's Disease
Abstract
Multifunctional mitochondrial enzyme 17 beta-hydroxysteroid dehydrogenase type 10 plays a role in the development of Alzheimer's disease. However, changes in its expression in the brain or cerebrospinal fluid are not fully specific for this type of dementia.
Our previous study revealed that complexes of the enzyme and amyloid beta in cerebrospinal fluid could serve as a more specific biomarker of Alzheimer's disease than either the enzyme or amyloid beta individually when compared to autoimmune multiple sclerosis. In this study, enzyme-linked immunosorbent assay and the surface plasmon resonance biosensor method were used to analyse cerebrospinal fluid of patients with various neuroinflammatory diseases.
Significant differences in the levels of the total enzyme, complexes, amyloid beta 1-42 and total tau/phospho-tau were found in Alzheimer's disease patients while differences in complexes, total amyloid beta and amyloid beta 1-42 were observed in patients with neuroinflammatory diseases (except for multiple sclerosis) when compared to non-neuroinflammatory controls. The interactions of the enzyme with amyloid appeared to depend strongly on neuroinflammation-sensitive amyloid beta.
Our data demonstrated that oligomerisation/aggregation of intracellular amyloid beta peptides was important in Alzheimer's disease while extracellular amyloid beta could play a role in neuroinflammatory diseases. Phospho-tau is currently the best biomarker of Alzheimer's disease.